• Isomorphic Labs is a high-risk, early-stage private opportunity, not yet available to most public investors; watch for its first human trials, now expected by the end of 2026, before treating its AI claims as proven.
• For public exposure, Novartis (NVS) and Eli Lilly (LLY) have milestone-based Isomorphic partnerships—up to $1.2 billion and $1.7 billion, respectively—but those payments depend on successful progress, and no resulting drug success is reported.
• Alphabet (GOOGL/GOOG) offers indirect exposure, but Isomorphic is estimated at only 0.2–0.3% of Alphabet’s valuation, so its progress is unlikely to materially drive Alphabet’s investment case.
• In AI drug discovery, prioritize verified clinical and regulatory milestones over technology claims or market-size forecasts; the insights provide no specific price targets or enough evidence to recommend RXRX, SDGR, or JNJ.

Isomorphic Labs (Private)

• Isomorphic Labs is an AI-driven drug-discovery company spun out of DeepMind and led by Demis Hassabis. Its goal is to use AI to design drugs, initially focusing on cancer and immune-related diseases.
• The company is building on AlphaFold 3 and its proprietary ISO-DDE drug-design engine. The transcript says Isomorphic is the only AI biotech with commercial access to AlphaFold 3, and that its own technical report showed ISO-DDE more than doubled AlphaFold 3’s accuracy on the hardest prediction cases.
• The opportunity is potentially large: AI drug discovery is estimated in the transcript at $2.35 billion, growing to $13 billion by 2033; pharmaceutical R&D spending is about $300 billion annually; and the global therapeutics market is estimated at more than $1.6 trillion.
• Isomorphic has partnerships with Novartis, Eli Lilly, and Johnson & Johnson. The deals include upfront payments, milestones, and potential royalties. The transcript cites up to $1.7 billion in future payments under the Lilly partnership and up to $1.2 billion under the Novartis deal, contingent on results.
• The transcript reports a $2.1 billion funding round and estimates Isomorphic’s valuation at $10–20 billion. It also describes total funding of $2.7 billion.
• The company has not yet treated patients. Its first human trials, originally expected by the end of 2025, were pushed to the end of 2026. The transcript says several cancer and immunology programs are in late preclinical stages.

Takeaways

• This is a high-potential but very early-stage private investment opportunity, not a proven drug developer. The key milestone to watch is whether its programs advance into human trials and eventually demonstrate safety and efficacy.
• The transcript specifically flags clinical and regulatory uncertainty, competition, and the risk that the valuation could run ahead of actual products. Milestone-based partnership payments also depend on successful progress.
• Private shares may be illiquid, and the transcript says Isomorphic may not need to go public soon. Investors without private-market access could get only indirect exposure through Alphabet, where Isomorphic is described as a very small part of the overall valuation.

Alphabet (GOOGL, GOOG)

• Alphabet is Isomorphic Labs’ parent company through Google DeepMind and is described as an early backer, with investment estimated at anywhere from hundreds of millions to more than $1 billion.
• The transcript estimates Isomorphic represents only about 0.2–0.3% of Alphabet’s valuation, so the company’s progress may have limited direct impact on Alphabet’s overall value.

Takeaways

• Alphabet offers public-market exposure to Isomorphic, but that exposure is highly diluted by Alphabet’s much larger businesses. Isomorphic’s success alone is unlikely to determine the investment case for Alphabet.

Novartis (NVS)

• Novartis partnered with Isomorphic in January 2024 and expanded the partnership in February 2025.
• The transcript says the agreement included $37.5 million upfront, with up to $1.2 billion in additional payments depending on results.

Takeaways

• The partnership gives Novartis access to AI-based drug-discovery work and may provide milestone-linked upside. The transcript does not establish that the collaboration has yet produced successful drugs, so its commercial impact remains uncertain.

Eli Lilly (LLY)

• Eli Lilly is collaborating with Isomorphic. The transcript says the deal included an upfront cash payment, though it does not provide the amount, and potential future payments of up to $1.7 billion.
• The transcript presents Lilly’s partnership as one example of major pharmaceutical companies paying to work with Isomorphic rather than simply investing in it.

Takeaways

• Lilly’s collaboration provides exposure to AI-enabled drug development, but the potential payments are contingent on milestones. The transcript gives no evidence that the partnership has yet resulted in an approved or commercially successful drug.

Johnson & Johnson (JNJ)

• Johnson & Johnson is named as an Isomorphic collaborator, but the transcript gives no financial terms or specific program details.

Takeaways

• The partnership is evidence of industry engagement with Isomorphic, but the transcript does not provide enough detail to assess its potential financial importance to J&J.

Recursion Pharmaceuticals (RXRX)

• Recursion is identified as a public company using AI to advance pharmaceutical research. The transcript says it merged with “Accentia” in 2024.
• It is presented as a competitor in the AI-biotech sector. The transcript does not provide Recursion’s valuation, pipeline results, or specific clinical milestones.

Takeaways

• Recursion offers public-market exposure to AI-enabled drug research, but the transcript provides limited company-specific evidence for assessing its prospects. Investors would need to compare clinical progress and commercial results rather than relying on the broad AI-drug-discovery theme alone.

Schrödinger (SDGR)

• Schrödinger is named as another company using AI to advance pharmaceutical research.
• The transcript provides no specific financial, partnership, or clinical details about Schrödinger.

Takeaways

• Schrödinger is a relevant public-market peer to research when evaluating AI drug discovery, but the transcript does not support a company-specific bullish or bearish conclusion.

Insilico Medicine (Hong Kong-listed)

• Insilico Medicine is described as a competitor that went public on the Hong Kong Exchange in December 2025.
• Unlike Isomorphic, Insilico is said to have already dosed patients in clinical trials, giving it a clinical-stage milestone that Isomorphic had not yet reached at the time discussed.

Takeaways

• The transcript portrays Insilico as further ahead on this particular clinical milestone, while Isomorphic is described as having a distinctive AlphaFold 3 advantage. Clinical progress, not technology claims alone, is a key point to compare.

AI Drug Discovery and Biotech

• The broader investment thesis is that AI could make drug research more efficient by predicting how drugs interact with proteins, identifying targets that were previously difficult to pursue, and reducing the current decade-long trial-and-error process.
• The transcript says drug approvals per dollar spent have declined over time, a challenge referred to as Eroom’s Law.
• It also emphasizes that predicting protein structures is not the same as producing effective medicines: AlphaFold has helped researchers investigate disease targets, but the transcript notes that it has not itself delivered cures.

Takeaways

• The sector has substantial potential, but AI capabilities and large market estimates do not establish that a company can develop safe, effective, approved drugs.
• For evaluating companies in this theme, focus on clinical milestones, regulatory progress, partnership economics, and evidence that technology translates into successful therapies.